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Protocol
AbstrAct
Introduction Advanced chronic kidney disease (CKD) 
has a major effect on the quality of life and health 
status of patients and requires accurate and responsive 
management. The use of electronic patient-reported 
outcome measures (ePROMs) could assist patients with 
advanced pre-dialysis CKD, and the clinicians responsible 
for their care, by identifying important changes in 
symptom burden in real time. We report the protocol for 
‘Using Patient-Reported Outcome measures (PROMs) to 
promote quality of care and safety in the management 
of patients with Advanced Chronic Kidney Disease’ 
(PRO-trACK) project, which will explore the feasibility 
and validity of an ePROM system for use in patients with 
advanced CKD.
Methods and analysis The project will use a mixed-
methods approach in three studies: (1) usability testing 
of the ePROM system involving up to 30 patients and 
focusing on acceptability and technical performance/
stability; (2) ascertaining the views of patient and clinician 
stakeholders on the optimal use and administration of the 
CKD ePROM system—this will involve qualitative face-
to-face/telephone interviewing with up to 30 patients or 
until saturation is achieved, focus groups with up to 15 
clinical staff, management and IT team members; (3) 
psychometric assessment of the system, within a cohort of 
at least 180 patients with advanced CKD, to establish the 
measurement properties of the ePROM.
Ethics and dissemination This project was approved 
by the West Midlands Edgbaston Research Ethics 
Committee (Reference 17/WM/0010) and received 
Health Research Authority (HRA) approval on 24 February 
2017. The findings from this project will be provided to 
clinicians at the Department of Renal Medicine, Queen 
Elizabeth Hospitals, Birmingham (QEHB), NHS England, 
presented at conferences and to the Kidney Patients’ 
Association, British Kidney Patient Association and the 
British Renal Society. Articles based on the findings 
will be written and submitted for publication in peer-
reviewed journals.
InTroducTIon
Chronic kidney disease (CKD) refers to a 
number of disorders affecting the structure 
and function of kidneys.1 The definition of 
CKD is based on sustained reduction in renal 
function (ie, ‘estimated glomerular filtra-
tion rate (eGFR) <60 mL/min per 1.73 m2 
for 3 months or more’) and/or evidence of 
structural or functional abnormalities of the 
kidneys regardless of clinical diagnosis.1 2 CKD 
is associated with other long-term conditions 
such as hypertension, cardiovascular diseases 
and diabetes that will increase the risk of ill 
health both when present singly and when 
associated with other long-term conditions.
CKD causes clinical signs and symptoms, 
particularly when the disease is advanced.3 
The most commonly experienced are fatigue, 
Strengths and limitations of this study
 ► While there is evidence to support the use 
of  electronic patient-reported outcome measures 
(ePROMs) in the management of other conditions, 
notably cancer, the evidence for the use of ePROMs 
in the management of patients with chronic kidney 
disease  (CKD) is currently limited. The  PRO-trACK 
project will help fill this evidence gap.
 ► By using a mixed-methods approach, the project will 
provide a rigorous exploration of the acceptability, 
validity and feasibility of the ePROM system for the 
management of patients with CKD.
 ► This project will only involve patients with CKD stages 
4 and 5 and patients on dialysis for <6 months. This 
is because the ePROM system is presently intended 
for patients with advanced CKD stages 4 and 5 who 
we hypothesise are likely to derive the most benefit.
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drowsiness, pain, pruritus and dry skin.4 These symp-
toms often occur concurrently and may negatively affect 
patients’ daily activities and their physical, emotional and 
psychological well-being,5 therefore impacting on the 
quality of life (QOL) of those affected, particularly as the 
disease progresses towards end-stage renal disease.6 7
The symptoms of CKD progression can be monitored 
using self-completed questionnaires known as patient-re-
ported outcome measures (PROMs), which capture 
information about health status from patients’ own point of 
view.8 Although commonly administered in paper format, 
PROMs can be completed as electronic patient-reported 
outcome measures (ePROMs) using multiple digital plat-
forms. This makes it possible to remotely monitor patients 
and generate ‘real time’ data about patient symptoms 
and QOL. As patients with advanced CKD are at risk 
of deteriorating rapidly and developing cardiovascular 
complications,9 the use of an ePROM system may help 
clinicians detect deterioration of symptoms and assist with 
the tailoring of treatment to the needs of each patient.10–12 
Health-related issues that matter to patients may also be 
identified using ePROM data, and this could potentially 
facilitate communication and shared decision-making 
between patients and their clinicians.13–15 In stable patients, 
the use of ePROMs may reduce the occurrence of unneces-
sary clinical appointments.12
In Denmark, the WestChronic ePROM System has been 
successfully implemented for tailoring the care of various 
patient groups,12 while in the UK, patients with cancer 
have been successfully monitored for the side effects of 
chemotherapy using the ePROM Advanced Symptom 
Management System.16 However, there is limited informa-
tion on the use of ePROMs in the management of adult 
patients with CKD in a routine clinical setting. Therefore, 
the aim of the project is to explore the feasibility and validity 
of an ePROM system for monitoring and assisting with the 
individual management of patients with advanced CKD.
Questionnaire selection and the eProM system
Selection of measures was informed by (1) a systematic 
review of measurement properties of PROMs used in 
patients with CKD17 and (2) feedback from the patient advi-
sory group (PAG). The systematic review found evidence 
to support the use of the Kidney Disease Quality of Life-
Short Form (KDQOL-SF) and Kidney Disease Quality of 
Life-36 (KDQOL-36). However, these two measures were 
validated by very few studies in our population of interest 
(stages 4 and 5 CKD). The review also identified the Inte-
grated Patient Outcome Scale-Renal (IPOS-Renal), which 
is currently undergoing validation through use in a number 
of renal units in the UK.
A PAG met prior to commencing the project and consid-
ered the acceptability, burdensomeness and relevance of 
the KDQOL-SF, KDQOL-36 and the IPOS-Renal for the 
target CKD group. The PAG members chose the KDQOL-36 
and IPOS-Renal as they were brief and easy to understand. 
Therefore, the decision was made to validate the electronic 
versions of these in the pre-dialysis population (stages 4 and 
5). The EuroQol Five-Dimension Five-Level (EQ-5D-5L) 
questionnaire will be used as a comparison measure for this 
validation study. See table 1 for a brief description of these 
three measures.
Table 1 Description of questionnaires
Measure Description
Kidney Disease 
Quality of Life-36 
(KDQOL-36)
A 36-item health-related quality of life (HRQOL) measure designed for use in patients with kidney 
disease undergoing dialysis. Derived from the Kidney Disease Quality of Life-Short Form.88
There are three disease-specific dimensions, namely (1) symptoms and problems (six items), (2) 
burden of kidney disease (four items) and (3) effects of kidney disease (eight items). It also includes 
two summary scales derived from the generic Short Form (SF)-12, namely (1) the physical component 
summary (six items) and (2) the mental component summary (six items).89
Response options vary for the items and range from 2 to 6. Questions 1, 8 and 12–36 have five 
response options; questions 2 and 3 have three response options; questions 4–7 have two response 
options; and questions 9–11 have six response options each. Total and subscale scores may be 
calculated using the KDQOL-36 scoring program. The raw scores for each item are converted linearly to 
a 0 to 100 range with higher scores indicating better HRQOL.88
Integrated Patient 
Outcome Scale-Renal
A symptom-specific measure with 11 questions for use with patients with advanced kidney disease to 
assess their care needs.
The questions relate to common symptoms patients with renal disease experience plus additional 
items such as information needs, practical issues and family anxiety.90 The first question has a free text 
response format. Questions 2 to 9 have five response options while questions 10 and 11 have three 
response options each. The measure is currently being validated by researchers at the Department of 
Palliative Care, Policy and Rehabilitation at King’s College London. Dimensions yet to be ascertained.
EuroQol Five-
Dimension Five-
Level questionnaire
A generic utility measure with a self-classifier and a visual analogue scale, which can be used to 
measure health status.91 92
The self-classifier includes five dimensions: (1) mobility, (2) self-care, (3) usual activities, (4) pain/
discomfort and (5) anxiety/depression.
This version of the measure has five levels of severity (response options) for each dimension. It is 
possible to describe 3125 different health states between 0 (dead) and 1 (perfect health).91 92
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The KDQOL-36 and the IPOS-Renal are free to use 
without charge as long as the developers are appropri-
ately acknowledged and cited. The EQ-5D-5L requires 
prior written consent and payment of licensing fees (if 
applicable). A licence will be obtained for this project.
The PRO-trACK project will consist of three studies, 
namely (1) usability testing with patients, (2) qualitative 
study with patients and clinicians, and (3) validation study 
with patients.
While the usability testing and qualitative interviews 
are related, they are distinct studies. The usability testing 
will focus on the actual experience of patients as they test 
the ePROM system while the qualitative interviews will 
explore the broader opinions of patients on the use of 
ePROMs in the NHS.
The content validation of the KDQOL-36 and the 
IPOS-Renal by patients and clinicians during the quali-
tative study as well as the results of the validation study 
will assist the research team with the final decision on 
which measure to take forward for the final version of the 
ePROM system.
The ePROM system will be designed as an electronic 
method of allowing patients with CKD to remotely self-re-
port their symptoms and QOL using a digital platform that 
is convenient to them (PC, tablet, smartphone, telephone 
voice recognition or scanned paper copy), providing 
important patient-centred data to the patients’ clinical 
team.
The ePROM system will be accessed via the secure 
electronic patient portal developed by the University 
Hospitals Birmingham NHS Foundation Trust, known 
as ‘myhealth@QEHB’ (see figure 1).18 myhealth@QEHB 
currently has 14 000 patient users and was awarded the 
prestigious E- Health Insider award in 2014.19 Around 
1200 patients with renal disease are currently signed up 
for myhealth@QEHB. At the moment, this is a voluntary 
system.
MeThods and analysIs
Project design
In this section, the project setting and eligibility criteria for 
participants will be described first as this will be the same for 
the three studies. Aspects of research methods specific to 
each study will be subsequently discussed separately.
Project setting
Queen Elizabeth Hospitals, Birmingham (QEHB) will be 
the host site for this project. Clinical staff at the Renal 
Unit, QEHB and academic researchers at the Centre 
for Patient-Reported Outcomes Research, University 
of Birmingham will be responsible for the conduct and 
management of the project. The nephrology service 
comprises 21 consultants, 30 junior doctors, and 20 
nurses and allied health professionals in the CKD team.
Project participants
Patient participants
For the project, we will recruit adult patients with 
advanced CKD stages 4 and 5 under the care of the renal 
services at QEHB, with eGFR <20 mL/min/1.73 m2 who 
have been counselled about treatment modalities for 
end-stage renal disease (ESRD). In addition, using the 
renal risk calculator, they must have a >20% projected risk 
of progressing to ESRD and requiring renal replacement 
therapy (RRT) or an eGFR <10 mL/min/1.73 m2 within 
2 years.20 The renal risk calculator is a model designed 
to use routinely collected laboratory tests to predict the 
progression of patients with CKD stages 3 to 5 to kidney 
failure.20
We have selected this group of patients as our main 
target for this project because, even though they have not 
yet reached ESRD, they are likely to have high symptom 
burden and a high risk of rapid clinical deterioration to 
renal failure. We hypothesise this group of patients are 
likely to derive the most benefit from an ePROM system. 
Figure 1 Screenshot of the myhealth@QEHB login page.
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The research team also is working on a related project 
focused on dialysis patients.
Patients who have commenced dialysis within 6 months 
will also be eligible to participate as we hypothesise they 
will be able to recall their symptoms and medical needs 
pre-dialysis. Participants will be required to converse in 
everyday English and provide informed consent.
Patients who have a recent history of acute kidney 
injury within the last 3 months, a comorbidity with a high 
level of symptoms or terminal illness likely to lead to the 
death within 6 months of participation will be excluded 
from the study.
We will aim to recruit different sets of eligible patients 
for each study in order to minimise participant burden. 
However, if patients voluntarily express an interest, they 
will be allowed to participate in more than one study 
as long as the renal team is satisfied with their health 
status.
Efforts will be made to recruit up to 30% of the study 
participants from minority ethnic groups to reflect the 
ethnic diversity of the patient catchment area.
Although our previous work does not show an influence 
of socioeconomic status on outcomes for CKD,21 we will 
be mindful of sample diversity in relation to sociodemo-
graphic variables such age, gender, ethnicity and other 
relevant sociodemographic factors. We will collect data 
on participant characteristics to monitor this as recruit-
ment and qualitative data collection progress. Although 
we appreciate that patient populations and research 
samples do not always represent such diversity, we will try 
to employ recruitment strategies that optimise our ability 
to recruit a diverse patient sample.
Clinicians and other professional staff
Clinicians who manage patients with CKD at the Renal 
Unit, QEHB and members of the myHealth team and 
hospital management staff who provide consent will be 
recruited for this project.
Recruitment methods
A member of the renal research team at QEHB will screen 
patients for eligibility using the electronic screening tools 
that are used for clinical purposes. This will identify 
patients who meet the eligibility criteria and the clinics 
they attend. Eligibility will be confirmed by direct review 
of the clinical records by the research nurse and a clini-
cian who are members of the renal care team, on the 
delegated duty log.
Patients will then be approached at clinic by a member 
of the renal care team and given patient information 
sheet to read. Further information about the study will 
be given and their immediate queries will be addressed. 
They will be contacted no earlier than 48 hours after the 
clinic visit to ascertain if they wish to participate in the 
study.
Clinicians and other professional staff will be recruited 
by the members of the research team and sent informa-
tion sheets via email.
study 1: usability testing
Usability testing will be conducted to evaluate the accept-
ability of the ePROM system.
Study objectives
 ► To determine whether patients can easily navigate the 
ePROM system.
 ► To determine if patients are able to complete the 
questionnaires successfully on their own and, if not, 
how much assistance they require.
 ► To determine the average length of time required to 
complete an ePROM report.
 ► To determine the level of satisfaction with the ePROM 
interface.
 ► To identify changes that might be required to improve 
user performance and satisfaction.
Data collection
Usability testing refers to the appraisal of a product 
or service by potential service users and involves the 
observation of such users completing a task within a 
predetermined scenario.22 23
The scenario for this study will be the self-report of a 
patient’s health status between clinic appointments using 
an electronic device such as a smartphone, tablet or PC/
laptop. Each patient will undergo a single one-to-one 
session with OLA, the project’s chief investigator (CI), 
and attempt to complete the three electronic question-
naires with as little assistance as possible.
The Concurrent Think Aloud (CTA) and Retrospec-
tive Probing (RP) moderating techniques will be used for 
this study.24 CTA involves the thinking aloud and vocali-
sation of participants’ thoughts during the session while 
RP refers to interviewing the participant following the 
completion of the session.24 The advantage of combining 
both techniques is that real-time feedback could be 
obtained for exploration by the CI afterwards.22
The CI will take detailed notes of the participants’ 
comments, actions, non-verbal cues and errors and pass 
minimal comments to encourage them to think aloud 
during the sessions.
Qualitative data will be collected in the form of a brief 
audio-recorded interview at the end of each test. The 
patients will be questioned based on the notes taken by 
the CI during the session. They will be encouraged to 
provide any recommendation to improve user experi-
ence.
Data analysis
Thematic analysis will be conducted on the qualitative 
data (see the analysis of patient interviews for more 
details), which will include the notes taken during the 
sessions and the transcripts of the post-test interview.
Quantitative data will be summarised using descriptive 
statistics such as proportions, averages, percentages and 
rates.22 Quantitative data will include successful comple-
tion rates, error-free rates and average time required for 
completion.
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Sample size
We will recruit up to 30 patients from QEHB for this study 
based on the recommendations found in literature.25 The 
process of improving the usability of any system is an iter-
ative one22; therefore, a minimum of two testing cycles 
will be conducted with the patients. The findings from 
the first test cycle will guide the process of improving the 
ePROM system before the second cycle is conducted.
study 2: qualitative study
This study will explore the views of stakeholders on the 
optimal use and administration of the CKD ePROM 
system.
Study 2a: patient interviews
Study objectives
 ► To determine which symptoms patients with CKD find 
most bothersome.
 ► To explore how acceptable ePROMs are.
 ► To determine how often patients will be willing to 
complete the ePROM and their preferred method of 
completion, that is, PC, smartphone, tablet, telephone 
voice recognition or paper completion.
 ► To explore the likely factors that may improve or 
discourage the completion of ePROMs.
 ► To explore how they would like to receive feedback 
from the clinical team regarding the ePROMs they 
provide.
Data collection
Semi-structured face-to-face interviews will be arranged 
to either coincide with patients’ scheduled clinic visit or 
held on a separate day if preferred. The option of a tele-
phone interview will also be given.
A topic guide will be used to provide a general direc-
tion for each interview and ensure that important issues 
are covered while allowing enough flexibility to capture 
other relevant themes that may arise during any session.
Interviews will be recorded using an encrypted digital 
audio recorder and transcribed by a professional tran-
scription company.
Data analysis
The transcripts will be analysed by the CI using the Nvivo 
10 software package by QSR International. Thematic anal-
ysis of the data will be conducted following the six steps 
described by Braun and Clarke.26 The process of analysis 
will begin with the CI ‘actively’ reading and engaging with 
the data set (ie, searching for patterns and meanings). 
The next phase will be the initial coding of the raw tran-
script data using the QSR software. Extracts will be coded 
inclusively (ie, a little surrounding data will be kept to 
retain contextual meaning).27
Phase 3 will involve the analysis and organisation of 
codes into potential themes. These initial themes will be 
revised and refined in the fourth phase on two levels. The 
first is at the level of coded data extracts to ensure they 
are coherent for each theme. The second level of analysis 
is to ensure the themes reflect the data set. During this 
phase, redundant codes and themes may be removed, 
revised or merged as required. Phase 5 will involve the 
definition of what each theme is and what it is not, and its 
importance in relation to the entire data and the research 
questions. The themes will be considered individually as 
well as in relation to other themes to ensure overlaps are 
kept to a minimum. The final phase will be the produc-
tion of the study report.
The project team (Independent of the CI) will 
randomly review a sample of transcripts for verification 
purposes.
Data analysis will be carried out simultaneously with 
data collection, and both will continue until no new 
themes emerge from the further analysis, that is, data 
saturation has been reached.28
Respondent validation will be undertaken, whereby a 
summary of the main points arising from the interview 
will be sent to each participant for comments.
Sample size
Based on experience from previous similar qualitative 
studies conducted by the research team, recruitment will 
continue until a target sample size of between 15 and 
30 patient participants is attained or until saturation is 
achieved.
Study 2b: focus groups with clinicians and other professional staff
Focus group discussions will be held with clinicians who 
manage patients with CKD at the Renal Unit, QEHB, 
members of the myHealth team and hospital manage-
ment staff as required.
Study objectives
 ► To evaluate and rate the relevance of the items of the 
ePROM questionnaires with clinical staff (content 
validation).
 ► To determine those factors that may improve or 
discourage the use of ePROM data by clinicians.
 ► To determine clinicians’ preferred method of 
displaying ePROM data.
Data collection
An independent member of staff will serve as chief 
moderator and direct the discussions while the CI will 
act as assistant moderator, making notes and observing 
the interactions within the groups. The discussions 
will be allowed to develop with minimum interference 
following a topic guide to ensure that all the main points 
are covered. Focus group sessions will be recorded using 
an encrypted digital audio recorder and transcribed by a 
professional transcription company.
Face-to-face or telephone interviews with clinicians and 
other professional staff may be conducted to explore 
their views on the use of PROMs. These interviews will 
require a maximum of 1 hour.
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Sample size
We will aim to include up to 15 participants in up to two 
focus groups (seven to eight participants in each group) 
and if necessary interview the same number of partici-
pants.
Data analysis
Thematic analysis will be conducted (see analysis of 
patient interviews for details).
study 3: eProM validation
The purpose of this study is to evaluate the measurement 
properties of the electronic versions of the KDQOL-36 
and the IPOS-Renal against the EQ-5D-5L and clinical 
data. At the end of this study, the most suitable question-
naire(s) would be taken forward for formal feasibility 
testing.
Study objectives
 ► To determine the reliability and validity of the ePROM 
questionnaires.
 ► To determine the ability of the ePROM questionnaires 
to detect change in a patient’s health over a period of 
time.
 ► To determine which of the two questionnaires is most 
suitable to take forward for formal feasibility testing.
Data collection
Patients will be registered on ‘myhealth@QEHB’ in order 
to access the ePROM system. There will be the option of 
completing paper versions if preferred. Time for ques-
tionnaire completion may be influenced by patients’ 
symptoms but should require no more than 1 hour.
All participants will be asked to complete the two ques-
tionnaires three times: at study entry, at 2 weeks after 
initial completion and at 6 months after initial comple-
tion. Completing the questionnaires at these time points 
will facilitate the comprehensive assessment of psycho-
metric properties.8 For definitions of measurement 
properties, see table 2.
Data analysis
Quantitative data will be analysed using statistical soft-
ware such as STATA. Where appropriate, analysis will be 
conducted separately for patients with CKD stages 4 and 
5 and patients on dialysis.
A disclaimer statement will be included in the patient 
information sheets for the validation study informing the 
patients that the questionnaires will not be assessed until 
the end of the study; therefore, patients should inform 
their clinician (eg, general practice or renal services) of 
any healthcare needs for management.
Psychometric evaluation
Classical test theory (CTT) and the Rasch measure-
ment model29 will be used to evaluate the psychometric 
properties of the ePROM versions of the KDQOL-36 
and IPOS-Renal. CTT is a traditional approach to ques-
tionnaire development, which postulates that a person’s 
observed score consists of their true score plus an addi-
tional measurement error score, and the underlying 
assumption is that this relationship is additive.30 31 This 
additive model involves the summation of item ratings on 
a Likert-type scale to obtain a total score; however, the 
values of the true score and error score cannot be deter-
mined and CTT does not describe the hierarchy of the 
items.30–32
Rasch analysis29 is one method of evaluating measure-
ment tools to ensure they deliver reliable and valid 
measurement and is increasingly being used in clinical 
research and practice for refinement and development 
of PROMs.33 The Rasch model operationalises axioms 
of additive conjoint measurement and tests the extent 
to which PROMs are unidimensional.34 Fit to the Rasch 
model is established through a number of fit statis-
tics.35 36 Analysis is an iterative process identifying and 
studying anomalies in the data and the extent to which 
data conforms to the Rasch model. The degree of fit 
achieved will identify the extent to which KDQOL-36 
and IPOS-Renal demonstrate construct validity, unidi-
mensionality and reliability.37 When data fit the Rasch 
model, it confirms that the PROMs are unidimensional 
and summation of scores from the KDQOL-36 and IPOS-
Renal is legitimate.35
CTT will be used to evaluate the reliability, construct 
validity and responsiveness while Rasch analysis will be 
done to complement the CTT assessment of structural 
validity of the two questionnaires.
cTT methods
Factor analysis 
Structural validity
Exploratory factor analysis will be used to evaluate 
the factor structure of the KDQOL-36 and the IPOS-
Renal.38 39 This will be conducted using principal 
component analysis (PCA) with orthogonal Varimax rota-
tion of quadrants.38 Factors will be identified based on 
the Scree test and the percentage of variance accounted 
for by a particular factor.40 41 Eigenvalues measure the 
amount of variation and factors will be required to have 
a minimum eigenvalue of 1.0.40 Subsequently, a confir-
matory factor analysis will be conducted to test whether 
the hypothesised factor models of the questionnaires are 
supported by actual data.38 42
Reliability
Internal consistency
Using baseline scores, Cronbach’s alpha43 will be calcu-
lated for the total scale and subscale scores of the 
KDQOL-36 and IPOS-Renal. Alpha values 0.70–0.90 will 
be deemed acceptable44–46 An ‘if item deleted’ analysis 
will be conducted to identify whether any items should be 
dropped from the scale.47
Test–retest reliability
The completion of the electronic questionnaires 2 
weeks after the initial completion will allow assessment 
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of the stability of the questionnaires.48 Intraclass 
correlation coefficients (ICCs) for agreement will be 
calculated on subscale and total scores using a two-way 
random effects model.49 50 ICC values >0.75 will indicate 
excellent test–retest reliability, values 0.40–0.75 will be 
considered good, while values <0.4 will indicate weak 
agreement.30 48 51
Measurement error
As we are not aware of values for measurement error 
and minimally important clinical change (MIC) for our 
population of interest, these will be calculated in this 
study. Measurement error will be calculated using the 
SE of measurement.49 52 The MIC will be determined for 
patients who commence dialysis within the study period 
using a patient-reported anchor-based method. This is 
regarded as the ideal method for calculating the MID as 
it captures the patients’ values directly.53 We will compare 
changes in measurement scores with a patient-re-
ported global rating of change scale as our reference 
‘anchor’.53–55 The measurement error and the MIC will 
assist with the assessment and interpretation of treatment 
outcomes and effects.56
Construct validity 
Convergent validity (hypothesis testing)
We have formulated the following hypotheses to test 
in order to establish convergent validity. Pearson’s or 
Spearman’s correlation coefficients will be calculated 
for correlations as appropriate. Pearson’s or Spearman’s 
correlation coefficients >0.40 will be considered accept-
able for scales that are theoretically related.57 58
Hypothesis 1
Each item of the KDQOL-36 and the IPOS-Renal will 
have a positive correlation >0.40 with its own hypothe-
sised subscale after correction for overlap.59 IPOS-Renal 
items will be correlated with their subscales once these 
have been established by factor analysis.
Hypothesis 2
The generic (SF-12) and the disease-specific domains 
of the KDQOL-36 will have weak to moderate positive 
correlations with each other as they are designed to assess 
different aspects of health-related quality of life.60 61
Hypothesis 3
Each subscale score of the KDQOL-36 will have positive 
correlations with the overall health rating score (question 
1 of KDQOL-36).62
Hypothesis 4
The generic (SF-12) subscales, the physical component 
summary and the mental component summary of the 
KDQOL-36 will have higher positive correlations with the 
utility scores of the EQ-5D-5L than the kidney-specific 
subscales of the KDQOL-36 and the symptom-specific 
scales of the IPOS-Renal.
Hypothesis 5
Clinical parameters specific to kidney disease such as the 
eGFR will correlate better with dialysis-targeted dimen-
sions of the KDQOL-36 and the IPOS-Renal than with 
generic dimensions of KDQOL-36.63
Hypothesis 6
The utility scores of the EuroQol Visual Analogue Scale 
will have a high positive correlation with the overall 
health rating scores of the KDQOL-36.
Hypothesis 7
The comparisons of the means of the lowest scoring 25th 
percentile and the higher scoring 75th percentile for 
each disease-specific subscale of the KDQOL-36 will be 
statistically significant (p values <0.05, using the Mann-
Whitney U test).64
Responsiveness
The questionnaires will be administered 6 months after 
the initial completion in order to assess the ability of the 
questionnaires in detecting changes in patients’ condi-
tion. Using Pearson’s correlation coefficient, we will test 
three hypotheses for responsiveness based on changes 
in scores as recommended by the Consensus-based 
Standards for the selection of health Measurement 
INstruments (COSMIN) group.65
Hypothesis 1
There will be significant changes in the QOL scores of 
patients who switch from conservative management to 
RRT within this period. Therefore, the QOL scores before 
and after commencing RRT will be compared using the 
Wilcoxon signed-rank test.66
Hypothesis 2
Changes in KDQOL-36 scores for patients who switch to 
RRT from conservative care will correlate negatively with 
changes in their creatinine values and correlate posi-
tively with changes in residual renal function and serum 
albumin.63 65
Hypothesis 3
There will be positive correlations between the global 
rating scale and the changes in KDQOL-36 scores for 
patients who switch to RRT from conservative care.65
In addition to these hypotheses, effect sizes (ES) and 
standardised response mean (SRM) will be calculated 
for patients with CKD stages 4 and 5 who were initially 
managed conservatively but progressed to renal failure 
(on RRT) during the study period.67 68
Higher ES or SRM indicate greater responsiveness 
and values up to 0.2 will be regarded as small, 0.5 
moderate and 0.8 as substantial according to Cohen’s 
criteria.69 Receiver operating characteristic curves will be 
used to establish a cut point for predicting transition to 
RRT.
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Application of Rasch analysis
The underlying assumption with the Rasch model is that 
individual items capture a single underlying trait, and 
therefore the summation of items from the KDQOL-36 or 
IPOS-Renal forms unidimensional scales. Rasch analysis is 
an iterative process that identifies and studies anomalies 
in the data and the extent to which KDQOL-36 or IPOS-
Renal data conform to the Rasch model and therefore 
the extent to which the instrument is unidimensional. 
Fit will be established using a variety of indicators and 
fit statistics.70 The Rasch Unidimensional Measurement 
Model software (RUMM2030)71 will be used to analyse 
KDQOL-36 and IPOS-Renal data.
KDQOL-36 has a mixture of dichotomous and poly-
tomous responses whereas the IPOS-Renal items are all 
polytomous using a Likert response format (see table 1). 
Affirmation of response categories by respondents 
should follow a logical sequence. As their perceived 
level of health improves/deteriorates, then responses 
should reflect this by affirming higher or lower scoring 
categories, moving from a score of 1, to 2, then 3, etc, 
on any item.72 Rasch-Andrich thresholds are the points 
between adjoining categories where the probability of 
affirming either category is 50/50, when responders’ 
perceived level of health is equidistantly captured by 
adjoining categories.73 Where there is agreement with this 
expected response hierarchy, thresholds appear ordered, 
and disordered thresholds are observable as a lack of 
consistency.73 Disordered thresholds can suggest poorly 
defined or redundant scoring categories, and therefore 
conceptual distinctions between categories may be impre-
cise. Responders then find it difficult to assign a category 
to their perceived health status or QOL.
Targeting will be established by examining the extent 
to which distributions of participants perceived QOL/
health status and levels of health identified by KDQOL-36 
and IPOS-Renal items are analogous. The position of 
each responder and item on the underlying construct is 
defined as the person’s ability and the item’s difficulty.31 
Therefore, responders with low levels of perceived health 
or QOL should only affirm items and scoring categories 
which capture low levels of health. The item which captures 
the average level of ability will be identified as having zero 
logits by RUMM2030. Therefore, when person and items 
are appropriately targeted, person mean location scores 
should approximate the zero value of the item locations. 
A positive mean value for responders’ estimated locations 
will suggest that responders’ average levels of health are 
higher than the average on the KDQOL-36. Conversely, 
negative person locations will confirm the opposite to be 
true.35
The person separation index (PSI) uses the logit values 
to estimate the internal reliability of the KDQOL-36 and 
IPOS-Renal and is conceptually equivalent to Cronbach’s 
alpha. It identifies the extent to which the instrument is 
able to discriminate between groups with different health 
states and the precision of the estimate for each person.74 
Minimum PSI value suggested for group use is 0.70 and 
for individual use 0.85.35
Individual tests of fit for each person and item will 
reflect the difference between responders observed 
and expected responses if data fit the Rasch model. 
RUMM2030 will automatically cluster responders into 
equivalent size groups (class intervals) according to their 
overall ability. A number of statistics use these class inter-
vals including χ2 statistics and residual values.75 Residuals 
are summations of individual item or person deviations 
from expected fit to the Rasch model, standardised as a 
z-score. Residual scores between ±2.5 indicate adequate 
fit to the Rasch model.75
A χ2 statistic will compare this difference, with a 
summed χ2 for each class interval contributing to the 
overall χ2 for that item. The χ2 for all items will then 
be summed to demonstrate the overall item-interaction 
statistic. A non-significant χ2 interaction statistic will indi-
cate theoretical fit to the Rasch model.75 A significant χ2 
will indicate the need for further evaluation to establish 
potential causes of misfit.
Differential item functioning (DIF) is a form of item 
bias that can affect fit to the model. DIF manifests itself 
as responses to individual items by sample subgroups 
(eg, gender or age group) being inconsistent with their 
overall perceived level of health.76 DIF will be identified 
using ANOVA and statistically significant probability 
(p<0.05, or a Bonferroni-corrected level). DIF for gender, 
age group and kidney disease stage will be examined.
Item independence is an underlying principle of the 
Rasch model.37 Response dependency occurs when a 
person’s response to one item determines the response to 
another item, and therefore responses are not indepen-
dent of each other.35 Residual correlation metrics (<0.3) 
will identify if response dependency is an issue.
Once the ‘Rasch factor’ is extracted, leftover residuals 
should not contain any patterns in the data.35 A PCA of the 
residuals will detect if multi-dimensionality is an issue.37 
Subsets of items identified by the negative and positive 
correlations from the PCA will be used to compare esti-
mates of responders’ health states on the two subsets. If no 
significant difference in the estimates is identified using 
independent t-test, then unidimensionality is assured. 
Tennant and Conaghan35 also state that the percentage 
of tests outside the range of −1.96 to 1.96 should not 
exceed 5%. Confidence intervals for the binomial test of 
proportions will be used; this is based on the number of 
significant tests and the lower bound should overlap the 
5% expected value for a non-significant test in order to 
confirm unidimensionality.35 If responders’ health state 
estimates are found to be significantly different in more 
than 5% of cases, this will indicate that the subtests are 
measuring different but related aspects of health states.35 
Where the scale is being used to measure changes over 
time, then using different but related subscales might be 
more appropriate.75
Finally, if the data fit the model, patient and item param-
eter estimates will be positioned on the same log-odds 
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units (logits) scale, although as independent parameters 
allowing a linear transformation of the raw scores to be 
used.75 Therefore, estimates of a patient’s level of health 
can be derived from the KDQOL-36 and IPOS-Renal data 
with confidence.
Sample size
There are various schools of thought regarding sample 
size requirements for validation studies.77–80 We aim to 
recruit at least 180 patients based on the recommen-
dations found in contemporary literature outlining 
psychometric best practice (5 to 10 times the number of 
variables in any given multivariate statistical model).77 78
Reimbursement and withdrawal
Reimbursement
All patients will be reimbursed for their time with a £20 
gift card.81 82 Light refreshments will be provided for 
focus group participants.
Withdrawal
Patient participants will be informed they have the right 
to freely withdraw from the study, for any reason, at any 
time prior to their data being integrated into the data 
set. They will not be required to supply a reason for their 
withdrawal and the decision will have no effect on their 
future medical care.
As focus group participants (clinicians and other 
professional staff) will be audio recorded as a group, they 
will be informed it will be impossible to withdraw their 
data during or after a focus group discussion. They will 
not be required to supply a reason for their withdrawal 
before a focus group discussion and the decision will have 
no effect on their employment.
dIscussIon
PROMs can be completed electronically, making it possible 
to remotely monitor symptoms in patients with CKD and 
generate ‘real time’ data, which may assist clinicians with 
the tailoring of treatment to the needs of each patient.12 
The use of ePROMs could potentially foster patient–clini-
cian communication and further support shared-decision 
between patients with CKD and their clinicians.13 14 The 
regular completion of ePROMs may decrease the need for 
stable patients with acceptable ePROM data to attend clin-
ical appointments, thus sparing them the financial burden 
and physical stress of travelling. This might free up appoint-
ment times for patients who actually need to be seen in 
clinic.12 In this manner, the use of PROMs may significantly 
improve the quality of life of patients with CKD.
At each stage of the project, when necessary, PAG 
meetings will be convened for their input and drafts of 
publication manuscripts reviewed by members of the 
group before submission to journals.
By employing a mixed-methods approach, the 
PRO-trACK project will provide evidence of the feasi-
bility and validity of the ePROM system in patients with 
advanced CKD.
eThIcs and dIsseMInaTIon
ethics and data management
This project was approved by the West Midlands Edgbaston 
Research Ethics Committee (Reference 17/WM/0010) 
and received Health Research Authority (HRA) Approval 
on 24 February 2017. It has also been included in the 
National Institute for Health Research (NIHR) Clinical 
Research Network (CRN) Portfolio (ID 33117).
Participant data (whether in electronic or paper 
format) will be acquired, anonymised, transferred and 
stored according to the Data Protection Act 199883; the 
Confidentiality—NHS Code of Practice84; the Caldicott 
principles85; the University of Birmingham Code of prac-
tice for research86; and the University of Birmingham 
Guidance on Out of Hours Activities and Lone Working.87
Only members of the research team will have access to 
the project data. The exception will be permissions given 
to authorised regulatory personnel in order to conduct 
audits and inspections on behalf of the ethics committee.
dissemination
The findings of the project will be provided to the Infor-
matics Team and the Nephrology Unit at the QEHB as 
required. Participants will be given a summary of the find-
ings, with reference to the full reports if desired.
Research article(s) based on the findings of the 
studies will be written and submitted for publication to 
peer-reviewed journals, and all contributors and their 
contributions to the study will be acknowledged. We will 
also disseminate our findings at seminars and confer-
ences both nationally and internationally.
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